A Phase I-IIa, Open label, Multi-Center, Dose Escalating Study to Evaluate the Safety of Intravenous Pegylated Liposomal Dexamethasone Sodium Phosphate (Oncocort) as Monotherapy in Patients with Previously Treated Progressive Multiple Myeloma
Latest Information Update: 09 Nov 2020
Price :
$35 *
At a glance
- Drugs Dexamethasone (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man
- Acronyms AMETHYST
- Sponsors Enceladus Pharmaceuticals
- 04 Nov 2020 Status changed from not yet recruiting to discontinued due to patient enrolment issues
- 15 Nov 2016 New trial record